Literature DB >> 27562873

Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV.

Kimberly K Scarsi1, Kristin M Darin2, Catherine A Chappell3, Stephanie M Nitz4, Mohammed Lamorde5.   

Abstract

Family planning options, including hormonal contraceptives, are essential for improving reproductive health among the more than 17 million women living with HIV worldwide. For these women, prevention of unintended pregnancy decreases maternal and child mortality, as well as reduces the risk of perinatal HIV transmission. Similarly, treatment of HIV with antiretroviral therapy (ART) is essential for reducing morbidity and mortality among HIV-positive individuals, as well as preventing HIV transmission between sexual partners or from mother to child. Importantly, despite the benefits of hormonal contraceptives, barriers to effective family planning methods exist for HIV-positive women. Specifically, drug-drug interactions can occur between some antiretroviral medications and some hormonal contraceptives, which may influence both contraceptive efficacy and tolerability. In addition, safety concerns have been raised about the impact of hormonal contraceptives on HIV disease progression, tolerability, and the risk of female-to-male HIV transmission. This review article summarizes the potential for drug-drug interactions, tolerability, and contraceptive effectiveness when hormonal contraceptives are combined with ART. In addition, the evidence surrounding the influence of hormonal contraceptives on HIV transmission and HIV disease progression in women living with HIV are summarized.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27562873      PMCID: PMC5048570          DOI: 10.1007/s40264-016-0452-7

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  86 in total

1.  The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women--effects on bleeding patterns, ovarian function and genital shedding of HIV.

Authors:  Oskari Heikinheimo; Päivi Lehtovirta; Jukka Suni; Jorma Paavonen
Journal:  Hum Reprod       Date:  2006-07-31       Impact factor: 6.918

2.  Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya.

Authors:  Catherine S Todd; Jennifer Deese; Meng Wang; David Hubacher; Markus J Steiner; Sheila Otunga; Lut Van Damme
Journal:  Contraception       Date:  2014-10-22       Impact factor: 3.375

3.  Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.

Authors:  Mary A Vogler; Kristine Patterson; Lori Kamemoto; Jeong-Gun Park; Heather Watts; Francesca Aweeka; Karin L Klingman; Susan E Cohn
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

4.  Female sex and oral contraceptive use accelerate nicotine metabolism.

Authors:  Neal L Benowitz; Christina N Lessov-Schlaggar; Gary E Swan; Peyton Jacob
Journal:  Clin Pharmacol Ther       Date:  2006-05       Impact factor: 6.875

5.  ACOG Committee Opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy.

Authors: 
Journal:  Obstet Gynecol       Date:  2009-12       Impact factor: 7.661

Review 6.  Drug interactions between antiretrovirals and hormonal contraceptives.

Authors:  Alice Tseng; Cara Hills-Nieminen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-02-21       Impact factor: 4.481

7.  Trends in contraceptive use.

Authors:  Jacqueline E Darroch
Journal:  Contraception       Date:  2012-10-04       Impact factor: 3.375

8.  Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells.

Authors:  P Martin; R Riley; D J Back; A Owen
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

9.  Intrauterine devices and pelvic inflammatory disease: an international perspective.

Authors:  T M Farley; M J Rosenberg; P J Rowe; J H Chen; O Meirik
Journal:  Lancet       Date:  1992-03-28       Impact factor: 79.321

10.  Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation.

Authors:  Sanna Palovaara; Olavi Pelkonen; Jouko Uusitalo; Stefan Lundgren; Kari Laine
Journal:  Clin Pharmacol Ther       Date:  2003-10       Impact factor: 6.875

View more
  19 in total

1.  Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.

Authors:  Owain Roberts; Rajith K R Rajoli; David J Back; Andrew Owen; Kristin M Darin; Courtney V Fletcher; Mohammed Lamorde; Kimberly K Scarsi; Marco Siccardi
Journal:  J Antimicrob Chemother       Date:  2018-04-01       Impact factor: 5.790

2.  Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma.

Authors:  Lauren R Cirrincione; Sujan Dilly Penchala; Kimberly K Scarsi; Anthony T Podany; Lee C Winchester; David J Back; Saye H Khoo; Courtney V Fletcher; Marco Siccardi; Laura J Else
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-03-12       Impact factor: 3.205

3.  Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.

Authors:  Catherine A Chappell; Mohammed Lamorde; Shadia Nakalema; Beatrice A Chen; Hope Mackline; Sharon A Riddler; Susan E Cohn; Kristin M Darin; Sharon L Achilles; Kimberly K Scarsi
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

4.  Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception.

Authors:  Jennifer E Balkus; Thesla Palanee-Phillips; Krishnaveni Reddy; Samantha Siva; Ishana Harkoo; Clemensia Nakabiito; Kenneth Kintu; Gonasangrie Nair; Catherine Chappell; Flavia Matovu Kiweewa; Samuel Kabwigu; Logashvari Naidoo; Nitesha Jeenarain; Mark Marzinke; Lydia Soto-Torres; Elizabeth R Brown; Jared M Baeten
Journal:  J Acquir Immune Defic Syndr       Date:  2017-10-01       Impact factor: 3.731

Review 5.  Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention.

Authors:  Melanie R Nicol; Joseph A Corbino; Mackenzie L Cottrell
Journal:  J Clin Pharmacol       Date:  2018-06-14       Impact factor: 3.126

Review 6.  Optimizing HIV prevention and care for transgender adults.

Authors:  Jordan E Lake; Jesse L Clark
Journal:  AIDS       Date:  2019-03-01       Impact factor: 4.177

Review 7.  Current and future contraceptive options for women living with HIV.

Authors:  Rena C Patel; Elizabeth A Bukusi; Jared M Baeten
Journal:  Expert Opin Pharmacother       Date:  2017-09-19       Impact factor: 3.889

8.  Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.

Authors:  Kimberly K Scarsi; Yoninah S Cramer; Susan L Rosenkranz; Francesca Aweeka; Baiba Berzins; Robert W Coombs; Kristine Coughlin; Laura E Moran; Carmen D Zorrilla; Victor Akelo; Mariam Aziz; Ruth K Friedman; David Gingrich; Shobha Swaminathan; Catherine Godfrey; Susan E Cohn
Journal:  Lancet HIV       Date:  2019-09       Impact factor: 12.767

9.  RP-HPLC method validation for fast extraction and quantification of Levonorgestrel drug from silicone based intrauterine device intended for in-process and finished formulation.

Authors:  Midhu George Veeran; Karthikeyan C; Bharaniraja B; Diksha Painuly; Abi Santhosh Aprem
Journal:  Daru       Date:  2021-05-01       Impact factor: 3.117

Review 10.  Adolescents and young adults with early acquired HIV infection in the united states: unique challenges in treatment and secondary prevention.

Authors:  Hasiya Yusuf; Allison Agwu
Journal:  Expert Rev Anti Infect Ther       Date:  2020-11-01       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.